APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global GLP-1 Drug Market Analysis and Forecast 2026-2032

29 December 2025197 pages

Choose your research edition.

Industry ResearchGLP-1 Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Drug Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal GLP-1 Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Drug Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global GLP-1 Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for GLP-1 Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of GLP-1 Drug include AstraZeneca, Boehringer Ingelheim, Eli Lilly, GlaxoSmithKline (GSK), Hanmi Pharmaceutical Co, Novo Nordisk, Pfizer Inc, Sanofi and Teva Pharmaceutical Industries Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for GLP-1 Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of GLP-1 Drug, also provides the sales of main regions and countries. Of the upcoming market potential for GLP-1 Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the GLP-1 Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global GLP-1 Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for GLP-1 Drug sales, projected growth trends, production technology, application and end-user industry.

GLP-1 Drug Segment by Company

AstraZeneca

Boehringer Ingelheim

Eli Lilly

GlaxoSmithKline (GSK)

Hanmi Pharmaceutical Co

Novo Nordisk

Pfizer Inc

Sanofi

Teva Pharmaceutical Industries Ltd

Gan & Lee Pharmaceuticals

Huadong Medicine

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

PegBio Co., Ltd

Shanghai Benemae Pharmaceutical Corporation

Tonghua Dongbao

GLP-1 Drug Segment by Type

Short-acting GLP-1 Drug

Long-acting GLP-1 Drug

GLP-1 Drug Segment by Application

Type 2 Diabetes (T2DM)

Alzheimer's Disease (AD)

Non-alcoholic Steatohepatitis (NASH)

Obesity

Cardiovascular and Cerebrovascular Diseases (CVD)

GLP-1 Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of GLP-1 Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, GLP-1 Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global GLP-1 Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Short-acting GLP-1 Drug Major Manufacturers Table 3. Long-acting GLP-1 Drug Major Manufacturers Table 4. Global GLP-1 Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Type 2 Diabetes (T2DM) Major Manufacturers Table 6. Alzheimer's Disease (AD) Major Manufacturers Table 7. Non-alcoholic Steatohepatitis (NASH) Major Manufacturers Table 8. Obesity Major Manufacturers Table 9. Cardiovascular and Cerebrovascular Diseases (CVD) Major Manufacturers Table 10. GLP-1 Drug Industry Trends Table 11. GLP-1 Drug Industry Drivers Table 12. GLP-1 Drug Industry Opportunities and Challenges Table 13. GLP-1 Drug Industry Restraints Table 14. Global GLP-1 Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global GLP-1 Drug Revenue by Region (2021-2026) & (US$ Million) Table 16. Global GLP-1 Drug Revenue by Region (2027-2032) & (US$ Million) Table 17. Global GLP-1 Drug Revenue Market Share by Region (2021-2026) Table 18. Global GLP-1 Drug Revenue Market Share by Region (2027-2032) Table 19. Global GLP-1 Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 20. Global GLP-1 Drug Sales by Region (2021-2026) & (K Units) Table 21. Global GLP-1 Drug Sales by Region (2027-2032) & (K Units) Table 22. Global GLP-1 Drug Sales Market Share by Region (2021-2026) Table 23. Global GLP-1 Drug Sales Market Share by Region (2027-2032) Table 24. Global GLP-1 Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global GLP-1 Drug Revenue Market Share by Manufacturers (2021-2026) Table 26. Global GLP-1 Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global GLP-1 Drug Sales Market Share by Manufacturers (2021-2026) Table 28. Global GLP-1 Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 29. Global GLP-1 Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global GLP-1 Drug Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global GLP-1 Drug Manufacturers, Product Type & Application Table 32. Global GLP-1 Drug Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global GLP-1 Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global GLP-1 Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 37. Global GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 38. Global GLP-1 Drug Revenue Market Share by Type (2021-2026) Table 39. Global GLP-1 Drug Revenue Market Share by Type (2027-2032) Table 40. Global GLP-1 Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 41. Global GLP-1 Drug Sales by Type (2021-2026) & (K Units) Table 42. Global GLP-1 Drug Sales by Type (2027-2032) & (K Units) Table 43. Global GLP-1 Drug Sales Market Share by Type (2021-2026) Table 44. Global GLP-1 Drug Sales Market Share by Type (2027-2032) Table 45. Global GLP-1 Drug Price by Type (2021-2026) & (US$/Unit) Table 46. Global GLP-1 Drug Price by Type (2027-2032) & (US$/Unit) Table 47. Global GLP-1 Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global GLP-1 Drug Revenue by Application (2021-2026) & (US$ Million) Table 49. Global GLP-1 Drug Revenue by Application (2027-2032) & (US$ Million) Table 50. Global GLP-1 Drug Revenue Market Share by Application (2021-2026) Table 51. Global GLP-1 Drug Revenue Market Share by Application (2027-2032) Table 52. Global GLP-1 Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 53. Global GLP-1 Drug Sales by Application (2021-2026) & (K Units) Table 54. Global GLP-1 Drug Sales by Application (2027-2032) & (K Units) Table 55. Global GLP-1 Drug Sales Market Share by Application (2021-2026) Table 56. Global GLP-1 Drug Sales Market Share by Application (2027-2032) Table 57. Global GLP-1 Drug Price by Application (2021-2026) & (US$/Unit) Table 58. Global GLP-1 Drug Price by Application (2027-2032) & (US$/Unit) Table 59. AstraZeneca Company Information Table 60. AstraZeneca Business Overview Table 61. AstraZeneca GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 62. AstraZeneca GLP-1 Drug Product Portfolio Table 63. AstraZeneca Recent Development Table 64. Boehringer Ingelheim Company Information Table 65. Boehringer Ingelheim Business Overview Table 66. Boehringer Ingelheim GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Boehringer Ingelheim GLP-1 Drug Product Portfolio Table 68. Boehringer Ingelheim Recent Development Table 69. Eli Lilly Company Information Table 70. Eli Lilly Business Overview Table 71. Eli Lilly GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Eli Lilly GLP-1 Drug Product Portfolio Table 73. Eli Lilly Recent Development Table 74. GlaxoSmithKline (GSK) Company Information Table 75. GlaxoSmithKline (GSK) Business Overview Table 76. GlaxoSmithKline (GSK) GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. GlaxoSmithKline (GSK) GLP-1 Drug Product Portfolio Table 78. GlaxoSmithKline (GSK) Recent Development Table 79. Hanmi Pharmaceutical Co Company Information Table 80. Hanmi Pharmaceutical Co Business Overview Table 81. Hanmi Pharmaceutical Co GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Hanmi Pharmaceutical Co GLP-1 Drug Product Portfolio Table 83. Hanmi Pharmaceutical Co Recent Development Table 84. Novo Nordisk Company Information Table 85. Novo Nordisk Business Overview Table 86. Novo Nordisk GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Novo Nordisk GLP-1 Drug Product Portfolio Table 88. Novo Nordisk Recent Development Table 89. Pfizer Inc Company Information Table 90. Pfizer Inc Business Overview Table 91. Pfizer Inc GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Pfizer Inc GLP-1 Drug Product Portfolio Table 93. Pfizer Inc Recent Development Table 94. Sanofi Company Information Table 95. Sanofi Business Overview Table 96. Sanofi GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. Sanofi GLP-1 Drug Product Portfolio Table 98. Sanofi Recent Development Table 99. Teva Pharmaceutical Industries Ltd Company Information Table 100. Teva Pharmaceutical Industries Ltd Business Overview Table 101. Teva Pharmaceutical Industries Ltd GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Teva Pharmaceutical Industries Ltd GLP-1 Drug Product Portfolio Table 103. Teva Pharmaceutical Industries Ltd Recent Development Table 104. Gan & Lee Pharmaceuticals Company Information Table 105. Gan & Lee Pharmaceuticals Business Overview Table 106. Gan & Lee Pharmaceuticals GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Gan & Lee Pharmaceuticals GLP-1 Drug Product Portfolio Table 108. Gan & Lee Pharmaceuticals Recent Development Table 109. Huadong Medicine Company Information Table 110. Huadong Medicine Business Overview Table 111. Huadong Medicine GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Huadong Medicine GLP-1 Drug Product Portfolio Table 113. Huadong Medicine Recent Development Table 114. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information Table 115. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview Table 116. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Product Portfolio Table 118. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Development Table 119. PegBio Co., Ltd Company Information Table 120. PegBio Co., Ltd Business Overview Table 121. PegBio Co., Ltd GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. PegBio Co., Ltd GLP-1 Drug Product Portfolio Table 123. PegBio Co., Ltd Recent Development Table 124. Shanghai Benemae Pharmaceutical Corporation Company Information Table 125. Shanghai Benemae Pharmaceutical Corporation Business Overview Table 126. Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Product Portfolio Table 128. Shanghai Benemae Pharmaceutical Corporation Recent Development Table 129. Tonghua Dongbao Company Information Table 130. Tonghua Dongbao Business Overview Table 131. Tonghua Dongbao GLP-1 Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Tonghua Dongbao GLP-1 Drug Product Portfolio Table 133. Tonghua Dongbao Recent Development Table 134. North America GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 135. North America GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 136. North America GLP-1 Drug Sales by Type (2021-2026) & (K Units) Table 137. North America GLP-1 Drug Sales by Type (2027-2032) & (K Units) Table 138. North America GLP-1 Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 139. North America GLP-1 Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 140. North America GLP-1 Drug Revenue by Application (2021-2026) & (US$ Million) Table 141. North America GLP-1 Drug Revenue by Application (2027-2032) & (US$ Million) Table 142. North America GLP-1 Drug Sales by Application (2021-2026) & (K Units) Table 143. North America GLP-1 Drug Sales by Application (2027-2032) & (K Units) Table 144. North America GLP-1 Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 145. North America GLP-1 Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 146. North America GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 147. North America GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 148. North America GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 149. North America GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 150. North America GLP-1 Drug Sales by Country (2021-2026) & (K Units) Table 151. North America GLP-1 Drug Sales by Country (2027-2032) & (K Units) Table 152. North America GLP-1 Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 153. North America GLP-1 Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 154. United States GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 155. Canada GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 156. Mexico GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 157. Europe GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 158. Europe GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 159. Europe GLP-1 Drug Sales by Type (2021-2026) & (K Units) Table 160. Europe GLP-1 Drug Sales by Type (2027-2032) & (K Units) Table 161. Europe GLP-1 Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 162. Europe GLP-1 Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 163. Europe GLP-1 Drug Revenue by Application (2021-2026) & (US$ Million) Table 164. Europe GLP-1 Drug Revenue by Application (2027-2032) & (US$ Million) Table 165. Europe GLP-1 Drug Sales by Application (2021-2026) & (K Units) Table 166. Europe GLP-1 Drug Sales by Application (2027-2032) & (K Units) Table 167. Europe GLP-1 Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 168. Europe GLP-1 Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 169. Europe GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 170. Europe GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 171. Europe GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 172. Europe GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 173. Europe GLP-1 Drug Sales by Country (2021-2026) & (K Units) Table 174. Europe GLP-1 Drug Sales by Country (2027-2032) & (K Units) Table 175. Europe GLP-1 Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 176. Europe GLP-1 Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 177. Germany GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 178. France GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 179. U.K. GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 180. Italy GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 181. Russia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 182. Spain GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 183. Netherlands GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 184. Switzerland GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 185. Sweden GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 186. Poland GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 187. China GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 188. China GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 189. China GLP-1 Drug Sales by Type (2021-2026) & (K Units) Table 190. China GLP-1 Drug Sales by Type (2027-2032) & (K Units) Table 191. China GLP-1 Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 192. China GLP-1 Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 193. China GLP-1 Drug Revenue by Application (2021-2026) & (US$ Million) Table 194. China GLP-1 Drug Revenue by Application (2027-2032) & (US$ Million) Table 195. China GLP-1 Drug Sales by Application (2021-2026) & (K Units) Table 196. China GLP-1 Drug Sales by Application (2027-2032) & (K Units) Table 197. China GLP-1 Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 198. China GLP-1 Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 199. Asia GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 200. Asia GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 201. Asia GLP-1 Drug Sales by Type (2021-2026) & (K Units) Table 202. Asia GLP-1 Drug Sales by Type (2027-2032) & (K Units) Table 203. Asia GLP-1 Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 204. Asia GLP-1 Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 205. Asia GLP-1 Drug Revenue by Application (2021-2026) & (US$ Million) Table 206. Asia GLP-1 Drug Revenue by Application (2027-2032) & (US$ Million) Table 207. Asia GLP-1 Drug Sales by Application (2021-2026) & (K Units) Table 208. Asia GLP-1 Drug Sales by Application (2027-2032) & (K Units) Table 209. Asia GLP-1 Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 210. Asia GLP-1 Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 211. Asia GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 212. Asia GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 213. Asia GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 214. Asia GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 215. Asia GLP-1 Drug Sales by Country (2021-2026) & (K Units) Table 216. Asia GLP-1 Drug Sales by Country (2027-2032) & (K Units) Table 217. Asia GLP-1 Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 218. Asia GLP-1 Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 219. Japan GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 220. South Korea GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 221. India GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 222. Australia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 223. Taiwan GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 224. Southeast Asia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 225. SAMEA GLP-1 Drug Revenue by Type (2021-2026) & (US$ Million) Table 226. SAMEA GLP-1 Drug Revenue by Type (2027-2032) & (US$ Million) Table 227. SAMEA GLP-1 Drug Sales by Type (2021-2026) & (K Units) Table 228. SAMEA GLP-1 Drug Sales by Type (2027-2032) & (K Units) Table 229. SAMEA GLP-1 Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 230. SAMEA GLP-1 Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 231. SAMEA GLP-1 Drug Revenue by Application (2021-2026) & (US$ Million) Table 232. SAMEA GLP-1 Drug Revenue by Application (2027-2032) & (US$ Million) Table 233. SAMEA GLP-1 Drug Sales by Application (2021-2026) & (K Units) Table 234. SAMEA GLP-1 Drug Sales by Application (2027-2032) & (K Units) Table 235. SAMEA GLP-1 Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 236. SAMEA GLP-1 Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 237. SAMEA GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 238. SAMEA GLP-1 Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 239. SAMEA GLP-1 Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 240. SAMEA GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 241. SAMEA GLP-1 Drug Sales by Country (2021-2026) & (K Units) Table 242. SAMEA GLP-1 Drug Sales by Country (2027-2032) & (K Units) Table 243. SAMEA GLP-1 Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 244. SAMEA GLP-1 Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 245. Brazil GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 246. Argentina GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 247. Chile GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 248. Colombia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 249. Peru GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 250. Saudi Arabia GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 251. Israel GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 252. UAE GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 253. Turkey GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 254. Iran GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 255. Egypt GLP-1 Drug Revenue (2021-2032) & (US$ Million) Table 256. Key Raw Materials Table 257. Raw Materials Key Suppliers Table 258. GLP-1 Drug Distributors List Table 259. GLP-1 Drug Customers List Table 260. Research Programs/Design for This Report Table 261. Authors List of This Report Table 262. Secondary Sources Table 263. Primary Sources List of Figures Figure 1. GLP-1 Drug Image Figure 2. Global GLP-1 Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Short-acting GLP-1 Drug Image Figure 5. Long-acting GLP-1 Drug Image Figure 6. Global GLP-1 Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global GLP-1 Drug Market Size Share 2021 VS 2025 VS 2032 Figure 8. Type 2 Diabetes (T2DM) Image Figure 9. Alzheimer's Disease (AD) Image Figure 10. Non-alcoholic Steatohepatitis (NASH) Image Figure 11. Obesity Image Figure 12. Cardiovascular and Cerebrovascular Diseases (CVD) Image Figure 13. Global GLP-1 Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global GLP-1 Drug Revenue (2021-2032) & (US$ Million) Figure 15. Global GLP-1 Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global GLP-1 Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global GLP-1 Drug Revenue Market Share by Region (2021-2032) Figure 18. Global GLP-1 Drug Sales (2021-2032) & (K Units) Figure 19. Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 20. Global GLP-1 Drug Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico GLP-1 Drug Sales YoY (2021-2032) & (K Units) Figure 22. Europe GLP-1 Drug Sales YoY (2021-2032) & (K Units) Figure 23. China GLP-1 Drug Sales YoY (2021-2032) & (K Units) Figure 24. Asia (Excluding China) GLP-1 Drug Sales YoY (2021-2032) & (K Units) Figure 25. South America, Middle East and Africa GLP-1 Drug Sales YoY (2021-2032) & (K Units) Figure 26. Global GLP-1 Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global GLP-1 Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global GLP-1 Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global GLP-1 Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global GLP-1 Drug Revenue Market Share by Type (2021-2032) Figure 32. Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 33. Global GLP-1 Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global GLP-1 Drug Sales Market Share by Type (2021-2032) Figure 35. Global GLP-1 Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global GLP-1 Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global GLP-1 Drug Revenue Market Share by Application (2021-2032) Figure 38. Global GLP-1 Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 39. Global GLP-1 Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global GLP-1 Drug Sales Market Share by Application (2021-2032) Figure 41. North America GLP-1 Drug Revenue Share by Type (2021-2032) Figure 42. North America GLP-1 Drug Sales Share by Type (2021-2032) Figure 43. North America GLP-1 Drug Revenue Share by Application (2021-2032) Figure 44. North America GLP-1 Drug Sales Share by Application (2021-2032) Figure 45. North America GLP-1 Drug Revenue Share by Country (2021-2032) Figure 46. North America GLP-1 Drug Sales Share by Country (2021-2032) Figure 47. Europe GLP-1 Drug Revenue Share by Type (2021-2032) Figure 48. Europe GLP-1 Drug Sales Share by Type (2021-2032) Figure 49. Europe GLP-1 Drug Revenue Share by Application (2021-2032) Figure 50. Europe GLP-1 Drug Sales Share by Application (2021-2032) Figure 51. Europe GLP-1 Drug Revenue Share by Country (2021-2032) Figure 52. Europe GLP-1 Drug Sales Share by Country (2021-2032) Figure 53. China GLP-1 Drug Revenue Share by Type (2021-2032) Figure 54. China GLP-1 Drug Sales Share by Type (2021-2032) Figure 55. China GLP-1 Drug Revenue Share by Application (2021-2032) Figure 56. China GLP-1 Drug Sales Share by Application (2021-2032) Figure 57. Asia GLP-1 Drug Revenue Share by Type (2021-2032) Figure 58. Asia GLP-1 Drug Sales Share by Type (2021-2032) Figure 59. Asia GLP-1 Drug Revenue Share by Application (2021-2032) Figure 60. Asia GLP-1 Drug Sales Share by Application (2021-2032) Figure 61. Asia GLP-1 Drug Revenue Share by Country (2021-2032) Figure 62. Asia GLP-1 Drug Sales Share by Country (2021-2032) Figure 63. SAMEA GLP-1 Drug Revenue Share by Type (2021-2032) Figure 64. SAMEA GLP-1 Drug Sales Share by Type (2021-2032) Figure 65. SAMEA GLP-1 Drug Revenue Share by Application (2021-2032) Figure 66. SAMEA GLP-1 Drug Sales Share by Application (2021-2032) Figure 67. SAMEA GLP-1 Drug Revenue Share by Country (2021-2032) Figure 68. SAMEA GLP-1 Drug Sales Share by Country (2021-2032) Figure 69. GLP-1 Drug Value Chain Figure 70. Manufacturing Cost Structure Figure 71. GLP-1 Drug Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Short-acting GLP-1 Drug
  • Long-acting GLP-1 Drug
Applications
  • Type 2 Diabetes (T2DM)
  • Alzheimer's Disease (AD)
  • Non-alcoholic Steatohepatitis (NASH)
  • Obesity
  • Cardiovascular and Cerebrovascular Diseases (CVD)
Companies covered
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline (GSK)
  • Hanmi Pharmaceutical Co
  • Novo Nordisk
  • Pfizer Inc
  • Sanofi
  • Teva Pharmaceutical Industries Ltd
  • Gan & Lee Pharmaceuticals
  • Huadong Medicine
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • PegBio Co., Ltd
  • Shanghai Benemae Pharmaceutical Corporation
  • Tonghua Dongbao

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 GLP-1 Drug Market by Type
  3. 1.2.1 Global GLP-1 Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Short-acting GLP-1 Drug
  5. 1.2.3 Long-acting GLP-1 Drug
  6. 1.3 GLP-1 Drug Market by Application
  7. 1.3.1 Global GLP-1 Drug Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Type 2 Diabetes (T2DM)
  9. 1.3.3 Alzheimer's Disease (AD)
  10. 1.3.4 Non-alcoholic Steatohepatitis (NASH)
  11. 1.3.5 Obesity
  12. 1.3.6 Cardiovascular and Cerebrovascular Diseases (CVD)
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 GLP-1 Drug Market Dynamics
  1. 2.1 GLP-1 Drug Industry Trends
  2. 2.2 GLP-1 Drug Industry Drivers
  3. 2.3 GLP-1 Drug Industry Opportunities and Challenges
  4. 2.4 GLP-1 Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global GLP-1 Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global GLP-1 Drug Revenue by Region
  3. 3.2.1 Global GLP-1 Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global GLP-1 Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global GLP-1 Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global GLP-1 Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global GLP-1 Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global GLP-1 Drug Sales by Region
  9. 3.4.1 Global GLP-1 Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global GLP-1 Drug Sales by Region (2021-2026)
  11. 3.4.3 Global GLP-1 Drug Sales by Region (2027-2032)
  12. 3.4.4 Global GLP-1 Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global GLP-1 Drug Revenue by Manufacturers
  2. 4.1.1 Global GLP-1 Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global GLP-1 Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global GLP-1 Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global GLP-1 Drug Sales by Manufacturers
  6. 4.2.1 Global GLP-1 Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global GLP-1 Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global GLP-1 Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global GLP-1 Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global GLP-1 Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global GLP-1 Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global GLP-1 Drug Manufacturers, Product Type & Application
  13. 4.7 Global GLP-1 Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global GLP-1 Drug Market CR5 and HHI
  16. 4.8.2 2025 GLP-1 Drug Tier 1, Tier 2, and Tier 3
5 GLP-1 Drug Market by Type
  1. 5.1 Global GLP-1 Drug Revenue by Type
  2. 5.1.1 Global GLP-1 Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global GLP-1 Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global GLP-1 Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global GLP-1 Drug Sales by Type
  6. 5.2.1 Global GLP-1 Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Drug Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global GLP-1 Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global GLP-1 Drug Price by Type
6 GLP-1 Drug Market by Application
  1. 6.1 Global GLP-1 Drug Revenue by Application
  2. 6.1.1 Global GLP-1 Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global GLP-1 Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global GLP-1 Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global GLP-1 Drug Sales by Application
  6. 6.2.1 Global GLP-1 Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global GLP-1 Drug Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global GLP-1 Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global GLP-1 Drug Price by Application
7 Company Profiles
  1. 7.1 AstraZeneca
  2. 7.1.1 AstraZeneca Company Information
  3. 7.1.2 AstraZeneca Business Overview
  4. 7.1.3 AstraZeneca GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 AstraZeneca GLP-1 Drug Product Portfolio
  6. 7.1.5 AstraZeneca Recent Developments
  7. 7.2 Boehringer Ingelheim
  8. 7.2.1 Boehringer Ingelheim Company Information
  9. 7.2.2 Boehringer Ingelheim Business Overview
  10. 7.2.3 Boehringer Ingelheim GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Boehringer Ingelheim GLP-1 Drug Product Portfolio
  12. 7.2.5 Boehringer Ingelheim Recent Developments
  13. 7.3 Eli Lilly
  14. 7.3.1 Eli Lilly Company Information
  15. 7.3.2 Eli Lilly Business Overview
  16. 7.3.3 Eli Lilly GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Eli Lilly GLP-1 Drug Product Portfolio
  18. 7.3.5 Eli Lilly Recent Developments
  19. 7.4 GlaxoSmithKline (GSK)
  20. 7.4.1 GlaxoSmithKline (GSK) Company Information
  21. 7.4.2 GlaxoSmithKline (GSK) Business Overview
  22. 7.4.3 GlaxoSmithKline (GSK) GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 GlaxoSmithKline (GSK) GLP-1 Drug Product Portfolio
  24. 7.4.5 GlaxoSmithKline (GSK) Recent Developments
  25. 7.5 Hanmi Pharmaceutical Co
  26. 7.5.1 Hanmi Pharmaceutical Co Company Information
  27. 7.5.2 Hanmi Pharmaceutical Co Business Overview
  28. 7.5.3 Hanmi Pharmaceutical Co GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Hanmi Pharmaceutical Co GLP-1 Drug Product Portfolio
  30. 7.5.5 Hanmi Pharmaceutical Co Recent Developments
  31. 7.6 Novo Nordisk
  32. 7.6.1 Novo Nordisk Company Information
  33. 7.6.2 Novo Nordisk Business Overview
  34. 7.6.3 Novo Nordisk GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Novo Nordisk GLP-1 Drug Product Portfolio
  36. 7.6.5 Novo Nordisk Recent Developments
  37. 7.7 Pfizer Inc
  38. 7.7.1 Pfizer Inc Company Information
  39. 7.7.2 Pfizer Inc Business Overview
  40. 7.7.3 Pfizer Inc GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Pfizer Inc GLP-1 Drug Product Portfolio
  42. 7.7.5 Pfizer Inc Recent Developments
  43. 7.8 Sanofi
  44. 7.8.1 Sanofi Company Information
  45. 7.8.2 Sanofi Business Overview
  46. 7.8.3 Sanofi GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Sanofi GLP-1 Drug Product Portfolio
  48. 7.8.5 Sanofi Recent Developments
  49. 7.9 Teva Pharmaceutical Industries Ltd
  50. 7.9.1 Teva Pharmaceutical Industries Ltd Company Information
  51. 7.9.2 Teva Pharmaceutical Industries Ltd Business Overview
  52. 7.9.3 Teva Pharmaceutical Industries Ltd GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Teva Pharmaceutical Industries Ltd GLP-1 Drug Product Portfolio
  54. 7.9.5 Teva Pharmaceutical Industries Ltd Recent Developments
  55. 7.10 Gan & Lee Pharmaceuticals
  56. 7.10.1 Gan & Lee Pharmaceuticals Company Information
  57. 7.10.2 Gan & Lee Pharmaceuticals Business Overview
  58. 7.10.3 Gan & Lee Pharmaceuticals GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Gan & Lee Pharmaceuticals GLP-1 Drug Product Portfolio
  60. 7.10.5 Gan & Lee Pharmaceuticals Recent Developments
  61. 7.11 Huadong Medicine
  62. 7.11.1 Huadong Medicine Company Information
  63. 7.11.2 Huadong Medicine Business Overview
  64. 7.11.3 Huadong Medicine GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Huadong Medicine GLP-1 Drug Product Portfolio
  66. 7.11.5 Huadong Medicine Recent Developments
  67. 7.12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  68. 7.12.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Information
  69. 7.12.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview
  70. 7.12.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Product Portfolio
  72. 7.12.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Recent Developments
  73. 7.13 PegBio Co., Ltd
  74. 7.13.1 PegBio Co., Ltd Company Information
  75. 7.13.2 PegBio Co., Ltd Business Overview
  76. 7.13.3 PegBio Co., Ltd GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 PegBio Co., Ltd GLP-1 Drug Product Portfolio
  78. 7.13.5 PegBio Co., Ltd Recent Developments
  79. 7.14 Shanghai Benemae Pharmaceutical Corporation
  80. 7.14.1 Shanghai Benemae Pharmaceutical Corporation Company Information
  81. 7.14.2 Shanghai Benemae Pharmaceutical Corporation Business Overview
  82. 7.14.3 Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Shanghai Benemae Pharmaceutical Corporation GLP-1 Drug Product Portfolio
  84. 7.14.5 Shanghai Benemae Pharmaceutical Corporation Recent Developments
  85. 7.15 Tonghua Dongbao
  86. 7.15.1 Tonghua Dongbao Company Information
  87. 7.15.2 Tonghua Dongbao Business Overview
  88. 7.15.3 Tonghua Dongbao GLP-1 Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Tonghua Dongbao GLP-1 Drug Product Portfolio
  90. 7.15.5 Tonghua Dongbao Recent Developments
8 North America
  1. 8.1 North America GLP-1 Drug Market Size by Type
  2. 8.1.1 North America GLP-1 Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America GLP-1 Drug Sales by Type (2021-2032)
  4. 8.1.3 North America GLP-1 Drug Price by Type (2021-2032)
  5. 8.2 North America GLP-1 Drug Market Size by Application
  6. 8.2.1 North America GLP-1 Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America GLP-1 Drug Sales by Application (2021-2032)
  8. 8.2.3 North America GLP-1 Drug Price by Application (2021-2032)
  9. 8.3 North America GLP-1 Drug Market Size by Country
  10. 8.3.1 North America GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America GLP-1 Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe GLP-1 Drug Market Size by Type
  2. 9.1.1 Europe GLP-1 Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe GLP-1 Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe GLP-1 Drug Price by Type (2021-2032)
  5. 9.2 Europe GLP-1 Drug Market Size by Application
  6. 9.2.1 Europe GLP-1 Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe GLP-1 Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe GLP-1 Drug Price by Application (2021-2032)
  9. 9.3 Europe GLP-1 Drug Market Size by Country
  10. 9.3.1 Europe GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe GLP-1 Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China GLP-1 Drug Market Size by Type
  2. 10.1.1 China GLP-1 Drug Revenue by Type (2021-2032)
  3. 10.1.2 China GLP-1 Drug Sales by Type (2021-2032)
  4. 10.1.3 China GLP-1 Drug Price by Type (2021-2032)
  5. 10.2 China GLP-1 Drug Market Size by Application
  6. 10.2.1 China GLP-1 Drug Revenue by Application (2021-2032)
  7. 10.2.2 China GLP-1 Drug Sales by Application (2021-2032)
  8. 10.2.3 China GLP-1 Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia GLP-1 Drug Market Size by Type
  2. 11.1.1 Asia GLP-1 Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia GLP-1 Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia GLP-1 Drug Price by Type (2021-2032)
  5. 11.2 Asia GLP-1 Drug Market Size by Application
  6. 11.2.1 Asia GLP-1 Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia GLP-1 Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia GLP-1 Drug Price by Application (2021-2032)
  9. 11.3 Asia GLP-1 Drug Market Size by Country
  10. 11.3.1 Asia GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia GLP-1 Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA GLP-1 Drug Market Size by Type
  2. 12.1.1 SAMEA GLP-1 Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA GLP-1 Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA GLP-1 Drug Price by Type (2021-2032)
  5. 12.2 SAMEA GLP-1 Drug Market Size by Application
  6. 12.2.1 SAMEA GLP-1 Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA GLP-1 Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA GLP-1 Drug Price by Application (2021-2032)
  9. 12.3 SAMEA GLP-1 Drug Market Size by Country
  10. 12.3.1 SAMEA GLP-1 Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA GLP-1 Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA GLP-1 Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 GLP-1 Drug Value Chain Analysis
  2. 13.1.1 GLP-1 Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 GLP-1 Drug Production Mode & Process
  6. 13.2 GLP-1 Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 GLP-1 Drug Distributors
  9. 13.2.3 GLP-1 Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst